What happened The stock of specialty telemedicine company Hims & Hers (NYSE: HIMS) took a big hit on Monday, cratering by 10.8%. It seems an analyst's modest price chop led to the investor sell-off. So what Early that morning, Credit Suisse prognosticator Jailendra Singh updated his price target on the stock, lowering it from $16 per share to $14. While doing so, however, he maintained his outperform (i.e., buy) recommendation. That's still a very bullish outlook on Hims & Hers' potential. Even though it's been reduced, that price target is still nearly double the stock's current level. Image source: Getty Images. Singh's slight revision comes two working days after Hims & Hers delivered impressive Q2 results with convincing beats on both the top and bottom lines, powered by revenue that increased nearly 70% on a year-over-year basis. The healthcare services company's 2021 revenue guidance was also well above expectations. The Credit Suisse analyst isn't alone in becoming more cautious about the stock. In the wake of Thursday's earnings release, Piper Sandler's Sean Wieland also trimmed his price target on the shares, from $11 to $10, while keeping his neutral recommendation. He believes that while that guidance is realistic, he is concerned about the viability of Hims and Hers' strategy for international expansion. Now what Neither analysis is sounding serious alarm bells about the future of Hims & Hers, rather they are fairly minor adjustments to existing views. So this sell-off feels a bit melodramatic, and could therefore provide an opportunity for optimists to jump on the Hims & Hers train. 10 stocks we like better than Hims & Hers HealthWhen our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and Hims & Hers Health wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of August 9, 2021 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.Source